These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 17149608)

  • 1. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
    Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
    Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
    Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
    Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
    J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
    Aranda E; Manzano JL; Rivera F; Galán M; Valladares-Ayerbes M; Pericay C; Safont MJ; Mendez MJ; Irigoyen A; Arrivi A; Sastre J; Díaz-Rubio E
    Ann Oncol; 2012 Jul; 23(7):1919-25. PubMed ID: 22156621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W;
    J Clin Oncol; 2007 May; 25(15):1960-6. PubMed ID: 17452677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
    Yang ZY; Yuan JQ; Di MY; Zheng DY; Chen JZ; Ding H; Wu XY; Huang YF; Mao C; Tang JL
    PLoS One; 2013; 8(3):e57528. PubMed ID: 23472089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
    Renouf DJ; Tang PA; Hedley D; Chen E; Kamel-Reid S; Tsao MS; Tran-Thanh D; Gill S; Dhani N; Au HJ; Wang L; Moore MJ
    Eur J Cancer; 2014 Jul; 50(11):1909-15. PubMed ID: 24857345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
    Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
    Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
    Okusaka T; Furuse J; Funakoshi A; Ioka T; Yamao K; Ohkawa S; Boku N; Komatsu Y; Nakamori S; Iguchi H; Ito T; Nakagawa K; Nakachi K
    Cancer Sci; 2011 Feb; 102(2):425-31. PubMed ID: 21175992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
    Takeda Y; Nakahira S; Katsura Y; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Suzuki R; Taniguchi H; Egawa C; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1884-6. PubMed ID: 24393954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.
    Samelis GF; Ekmektzoglou K; Tsiakou A; Giannakaki S; Konstadoulakis M
    Hepatogastroenterology; 2011; 58(110-111):1776-81. PubMed ID: 21940348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
    Ardavanis A; Kountourakis P; Karagiannis A; Doufexis D; Tzovaras AA; Rigatos G
    Anticancer Res; 2009 Dec; 29(12):5211-7. PubMed ID: 20044638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
    Van Cutsem E; Li CP; Nowara E; Aprile G; Moore M; Federowicz I; Van Laethem JL; Hsu C; Tham CK; Stemmer SM; Lipp R; Zeaiter A; Fittipaldo A; Csutor Z; Klughammer B; Meng X; Ciuleanu T
    Br J Cancer; 2014 Nov; 111(11):2067-75. PubMed ID: 25247318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.